Antares Pharma Company Profile (NYSE:AIS)

About Antares Pharma (NYSE:AIS)

Antares Pharma logoAntares Pharma, Inc. (Antares) is a pharmaceutical company that focuses on self-injection pharmaceutical products and technologies and gel-based products. The Company’s subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares has a multi-product deal with Teva Pharmaceutical Industries, Ltd. (Teva) that includes Tev-Tropin human growth hormone and has partnerships with Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR) that include their human growth hormone (hGH) products. In the gel-based area, its lead product candidate, Anturol, an oxybutynin Advanced Transdermal Delivery (ATD) gel for the treatment of overactive bladder (OAB), was under evaluation in a Phase III trial as of December 31, 2009.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSE:AIS
  • CUSIP: N/A
  • Web: N/A
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
  • Dividend Yield: 1.0%

Frequently Asked Questions for Antares Pharma (NYSE:AIS)

What is Antares Pharma's stock symbol?

Antares Pharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIS."

Who are some of Antares Pharma's key competitors?

How do I buy Antares Pharma stock?

Shares of Antares Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

MarketBeat Community Rating for Antares Pharma (NYSE AIS)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Antares Pharma (NYSE:AIS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Antares Pharma (NYSE:AIS)
Price Target History for Antares Pharma (NYSE:AIS)
Analysts' Ratings History for Antares Pharma (NYSE:AIS)
No equities research coverage for this company has been tracked by


Earnings History for Antares Pharma (NYSE:AIS)
Earnings by Quarter for Antares Pharma (NYSE:AIS)
Earnings History by Quarter for Antares Pharma (NYSE AIS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2013Q4 12($0.03)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Antares Pharma (NYSE:AIS)

No earnings estimates for this company have been tracked by


Dividend History for Antares Pharma (NYSE:AIS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Antares Pharma (NYSE:AIS)
No insider trades for this company have been tracked by


Headline Trends for Antares Pharma (NYSE:AIS)
Latest Headlines for Antares Pharma (NYSE:AIS)
No headlines for this company have been tracked by



Antares Pharma (AIS) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.